WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement



Status:Recruiting
Conditions:Atrial Fibrillation, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:11/2/2018
Start Date:December 15, 2017
End Date:December 2020
Contact:Allison Kirkholder, BSN
Email:kirkhoa@ccf.org
Phone:216.445.8070

Use our guide to learn which trials are right for you!

WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement

To evaluate the safety and effectiveness of the left atrial appendage occlusion with WATCHMAN
Device in prevention of stroke and bleeding in patients with atrial fibrillation (AF)
undergoing transcatheter aortic valve replacement (TAVR).

WATCH-TAVR is a prospective, multicenter, randomized controlled trial. Only centers with
approval for commercial WATCHMAN implantation will be included in this trial. Subjects will
be enrolled at up to 25 centers in the United States. There will be up to 312 subjects
enrolled, with 156 patients randomized to TAVR + medical therapy and 156 patients randomized
to simultaneous TAVR+WATCHMAN to accumulate the necessary 191 primary events. Enrollment is
expected to occur over the course of 18 months. Patients will be followed for a total of 2
years. Patients with non-valvular AF undergoing standard of care commercial TAVR will be
enrolled in the trial.

For patients who receive the WATCHMAN device, plan of care will follow WATCHMAN
labeling.Patients randomized to receive the WATCHMAN device will receive anticoagulation with
warfarin and aspirin for 6 weeks after the procedure. After 6 weeks, the plan of care will
follow WATCHMAN labeling. Patients randomized to the TAVR + medical therapy arm will be
treated in accordance with standard of care with either warfarin, other
anticoagulant/antiplatelet therapy, or no anticoagulation at the discretion of the treating
physician. All patients will continue to receive routine post-TAVR follow-up and
care.Patients will be monitored for primary and secondary endpoints as outlined. Baseline
information and laboratory data will be collected as described in the protocol.

Inclusion Criteria:

1. Men and women ≥ 18 years of age.

2. The patient meets criteria for and is scheduled to undergo TAVR procedure

3. The patient has documented paroxysmal, persistent, or permanent atrial fibrillation.

4. The patient meets the WATCHMAN labeling guidelines and is eligible to undergo the
WATCHMAN implantation procedure.

5. The patient is eligible for short term warfarin therapy.

6. The patient or legal representative is able to understand and willing to provide
written informed consent to participate in the trial.

7. The patient is able and willing to return for required follow-up visits and
examinations.

Exclusion Criteria:

1. The patient had a stroke or TIA within the last 6 months prior to enrollment.

2. Contraindication for short term anticoagulation.

3 .Moderate or severe Mitral Stenosis with mean gradient across Mitral Valve >10 mm Hg or
Mitral Valve Area < 1.2cm2.

4. The patient has symptomatic carotid disease (i.e.,carotid stenosis ≥ 50% associated with
ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric
TIAs or ipsilateral stroke within 6 months).

5. Prior occlusion of LAA.

6. The patient has an implanted mechanical mitral valve.

7. The patient requires long-term warfarin therapy due to:

1. Secondary to conditions such as prior arterial embolism or other indications such as
pulmonary embolism or deep vein thrombosis within the previous 6 months

2. The patient is in a hypercoaguable state; exclude the patient if per medical record
documentation, the patient meets any of the following criteria:

- Thrombosis occurring ≤ 40 years of age

- Idiopathic or recurrent VTE (venous thrombo-embolism)

- Thrombosis at an unusual site (cerebral veins, hepatic veins, renal veins, IVC,
mesenteric veins)

- Family history of VTE or of inherited prothrombotic disorder,
recurrence/extension of thrombosis while adequately anticoagulated.

8. The patient is actively enrolled in another trial of a cardiovascular device
or an investigational drug (post-market study participation and registries are
acceptable).

9. The patient is pregnant or pregnancy is planned during the course of the
investigation if patient is of child bearing potential.

10. Any clinically significant medical condition or presence of any laboratory
abnormality prior to randomization that is considered by the investigator to be
clinically important and could interfere with the conduct of the study or not
meeting procedure guidelines for TAVR or WATCHMAN.

11. The patient has a life expectancy of less than two years.
We found this trial at
23
sites
Plano, Texas 75093
Principal Investigator: Srini Potluri, MD
Phone: 469-814-4818
?
mi
from
Plano, TX
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: A. Krishnaswamy, MD
Phone: 216-445-6397
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbus, Ohio 43214
Principal Investigator: Carlos Sanchez, MD
Phone: 614-566-5768
?
mi
from
Columbus, OH
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: William O'Neil, MD
Phone: 313-916-4475
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Fort Wayne, Indiana 46805
Principal Investigator: Roy Robertson, MD
Phone: 260-266-5583
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Fort Worth, Texas 76107
Principal Investigator: Amir Malik, MD
Phone: 817-707-8703
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46290
Principal Investigator: James Hermiller, MD
Phone: 317-583-6319
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Jacksonville, Florida 32207
Principal Investigator: Ruby Satpathy, MD
Phone: 904-202-7218
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Loveland, Colorado 80538
Principal Investigator: Justin Strote, MD
Phone: 970-624-1682
?
mi
from
Loveland, CO
Click here to add this to my saved trials
Morristown, New Jersey 07962
Principal Investigator: Philippe Genereux, MD
Phone: 973-971-4205
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
5121 S Cottonwood St
Murray, Utah 84157
(801) 507-7000
Principal Investigator: Brian K Whisenant, MD
Phone: 801-507-4925
Intermountain Medical Center Intermountain Medical Center is one of the most technologically advanced and patient-friendly...
?
mi
from
Murray, UT
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: John Forrest, MD
Phone: 203-737-1868
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Principal Investigator: Martin Leon, MD
Phone: 212-342-3485
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
Phoenix, Arizona 85006
Principal Investigator: Ashish Pershad, MD
Phone: 602-827-9963
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: John Lasala, MD
Phone: 314-747-1417
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Saint Petersburg, Florida 33709
Principal Investigator: Jessi Klein, DO
Phone: 727-521-5392
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Santa Barbara, California 93105
Principal Investigator: Joseph Aragon, MD
Phone: 805-569-7461
?
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Springfield, Illinois 62701
Principal Investigator: Nilesh Goswami, MD
Phone: 217-492-9100
?
mi
from
Springfield, IL
Click here to add this to my saved trials
Tallahassee, Florida 32308
Principal Investigator: Wayne Batchelor, MD
Phone: 850-431-5024
?
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Washington, District of Columbia
Principal Investigator: Ron Waksman, MD
Phone: 202-877-2713
?
mi
from
Washington,
Click here to add this to my saved trials
West Columbia, South Carolina 29169
Principal Investigator: Robert Leonardi, MD
Phone: 803-744-4909
?
mi
from
West Columbia, SC
Click here to add this to my saved trials
Wormleysburg, Pennsylvania 17043
Principal Investigator: Hemal Gada, MD
Phone: 717-782-5904
?
mi
from
Wormleysburg, PA
Click here to add this to my saved trials
York, Pennsylvania 17403
Principal Investigator: James E Harvey, MD
Phone: 717-851-5153
?
mi
from
York, PA
Click here to add this to my saved trials